Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 7, 2018, Pages 547-554

  Packer, Milton ^a   Claggett, Brian ^b   Lefkowitz, Martin P ^c   McMurray, John J V ^d   Rouleau, Jean L ^e   Solomon, Scott D ^b   Zile, Michael R ^f  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e MONTREAL HEART INSTITUTE   (Canada)

^f RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ENALAPRIL; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE; VALSARTAN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DETERIORATION; DISEASE SEVERITY; DRUG EFFECT; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; AGED; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; KIDNEY DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

AGED; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENALAPRIL; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; NEPRILYSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TREATMENT OUTCOME; VALSARTAN;

EID: 85045334293     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(18)30100-1     Document Type: Article

References (30)

1. Packer, M, McMurray, JJV, Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet 389 (2017), 1831–1840.
2. Antezana, M, Sullivan, SR, Usui, M, et al. Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers. J Invest Dermatol 119 (2002), 1400–1404.
3. Hara, H, Oh-hashi, K, Yoneda, S, et al. Elevated neprilysin activity in vitreous of patients with proliferative diabetic retinopathy. Mol Vis 12 (2006), 977–982.
4. Chattington, PD, Anderson, JV, Rees, LH, Leese, GP, Peters, JR, Vora, JP, Atrial natriuretic peptide in type 2 diabetes mellitus: response to a physiological mixed meal and relationship to renal function. Diabet Med 15 (1998), 375–379.
5. Gans, RO, Bilo, HJ, Donker, AJ, The renal response to exogenous insulin in non-insulin-dependent diabetes mellitus in relation to blood pressure and cardiovascular hormonal status. Nephrol Dial Transplant 11 (1996), 794–802.
6. Das, S, Au, E, Krazit, ST, Pandey, KN, Targeted disruption of guanylyl cyclase-A/natriuretic peptide receptor-A gene provokes renal fibrosis and remodeling in null mutant mice: role of proinflammatory cytokines. Endocrinology 151 (2010), 5841–5850.
7. Cheng, ZJ, Grönholm, T, Louhelainen, M, et al. Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats. J Hypertens 23 (2005), 1757–1770.
8. McMurray, JJ, Packer, M, Desai, AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
9. Kristensen, SL, Preiss, D, Jhund, PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail, 9, 2016, e002560.
10. Brenner, BM, Cooper, ME, de Zeeuw, D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
11. Halbesma, N, Brantsma, AH, Bakker, SJ, et al. Gender differences in predictors of the decline of renal function in the general population. Kidney Int 74 (2008), 505–512.
12. Hou, J, Xiong, W, Cao, L, Wen, X, Li, A, Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis. Clin Ther 37 (2015), 2086–2103.
13. Wanner, C, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
14. Cornel, JH, Bakris, GL, Stevens, SR, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care 39 (2016), 2304–2310.
15. Mann, JFE, Ørsted, DD, Brown-Frandsen, K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 (2017), 839–848.
16. Packer, M, Lee, WH, Medina, N, Yushak, M, Kessler, PD, Gottlieb, SS, Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. Am J Med 82 (1987), 1119–1126.
17. Rossignol, P, Dobre, D, McMurray, JJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7 (2014), 51–58.
18. Packer, M, Califf, RM, Konstam, MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 (2002), 920–926.
19. Seferovic, JP, Claggett, B, Seidelmann, SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5 (2017), 333–340.
20. Helal, I, Fick-Brosnahan, GM, Reed-Gitomer, B, Schrier, RW, Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 8 (2012), 293–300.
21. Sakamoto, K, Kikkawa, R, Haneda, M, Shigeta, Y, Prevention of glomerular hyperfiltration in rats with streptozotocin-induced diabetes by an atrial natriuretic peptide receptor antagonist. Diabetologia 38 (1995), 536–542.
22. Jacobs, EM, Vervoort, G, Branten, AJ, Klasen, I, Smits, P, Wetzels, JF, Atrial natriuretic peptide increases albuminuria in type I diabetic patients: evidence for blockade of tubular protein reabsorption. Eur J Clin Invest 29 (1999), 109–115.
23. Knecht, M, Pagel, I, Langenickel, T, et al. Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci 71 (2002), 2701–2712.
24. Packer, M, Activation and inhibition of sodium-hydrogen exchange is a mechanism that links the pathophysiology and treatment of diabetes with that of heart failure. Circulation 136 (2017), 1548–1559.
25. Braga-Sobrinho, C, Leite-Dellova, DC, Mello-Aires, M, Action of ANP on the nongenomic dose-dependent biphasic effect of aldosterone on NHE1 in proximal S3 segment. J Steroid Biochem Mol Biol 128 (2012), 89–97.
26. Lessa, LM, Carraro-Lacroix, LR, Crajoinas, RO, et al. Mechanisms underlying the inhibitory effects of uroguanylin on NHE3 transport activity in renal proximal tubule. Am J Physiol Renal Physiol 303 (2012), F1399–F1408.
27. Hallow, KM, Gebremichael, Y, Helmlinger, G, Vallon, V, Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis. Am J Physiol Renal Physiol 312 (2017), F819–F835.
28. Thomson, SC, Deng, A, Cyclic GMP mediates influence of macula densa nitric oxide over tubuloglomerular feedback. Kidney Blood Press Res 26 (2003), 10–18.
29. Wang, BH, von Lueder, TG, Kompa, AR, et al. Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis. Int J Cardiol 186 (2015), 104–105.
30. Melsom, T, Schei, J, Stefansson, VT, et al. Prediabetes and risk of glomerular hyperfiltration and albuminuria in the general nondiabetic population: a prospective cohort study. Am J Kidney Dis 67 (2016), 841–850.